Androgenic Alopecia Clinical Trial
Official title:
A Phase-I, Open Label, Multi-Centre Clinical Study to Assess the Safety, Tolerability and Usability of FOL100 Lotion in Comparison to Oral Finasteride, for the Treatment of Androgenetic Alopecia
The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events. It is also aimed at indicating effectiveness as compared with oral Finasteride 1mg. In this non-blinded study, each patient will choose his preferred arm (oral finasteride or FOL100 location). During the study, safety and efficacy will be measured as well as usability.
Status | Recruiting |
Enrollment | 90 |
Est. completion date | February 2025 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: 1. Written informed consent will be signed by the subject before starting any study related procedures. 2. Male subject between the ages of 18 to 45 years old. 3. Male subject with mild to moderate vertex male-pattern hair loss, classified as grade III vertex to V, according to the modified Norwood/Hamilton Scale. 4. Subject must be willing to maintain normal shampooing habits and products during the study. 5. Fitzpatrick skin phototype classification of I-IV. 6. Subjects will agree to maintain the same haircut and color throughout the study, with no significant changes that will interfere with study objectives, as determined by the investigator. 7. Ability to understand and cooperate with the investigator and to comply with the requirements of the study protocol. Exclusion Criteria: 1. Clinically significant abnormal skin findings on the scalp, which in the opinion of the investigator, could interfere with the aim of the study; in particular, abrasion, actinic keratosis, inflammatory disorders, or any other abnormality. 2. Hair transplant surgery or hair weaving. 3. Clinically significant and active physical illness that could interfere with study objectives or may risk patient safety as determined by the Investigator during screening. 4. Ascertained or presumptive hypersensitivity to the active principle and/or any of the formulation ingredients; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of the investigator may affect subject safety or the outcome of the study. 5. History of local infections of the skin or subcutaneous tissues of the head within 3 months prior to study enrollment. 6. Clinically significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, or neurological diseases, which in the opinion of the investigator may affect subject safety or the outcome of the study. 7. Suspicion of malignancy, including prostate cancer. 8. Subject whose sexual partner(s) is pregnant or plan to become pregnant. 9. Concurrent use of systemic corticosteroids, topical corticosteroids in the area treated in the study, anabolic steroids, or over the counter "hair restorers". 10. Use of any of the following products 1 year for systemic use and 6 months for topical use: minoxidil (topical or oral), zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine ,benoxaprofen, tamoxifen, phenothiazines or cytotoxic agents. 11. Use of oral finasteride or dutasteride, within 18 months prior to enrollment and 6 months prior to enrollment for any topical medication that is considered to affect hair growth. 12. Use of a therapeutic shampoo for hair loss within 1 month prior to enrollment. 13. Light or laser treatment of scalp within 3 months prior to enrollment. 14. Unwilling to undergo a superficial ink marking on the scalp vertex during V0. |
Country | Name | City | State |
---|---|---|---|
Israel | Rabin Medical Center | Petah tikva | |
Israel | Sheba Medical Center | Ramat Gan | |
Israel | Sourasky Medical Center | Tel Aviv |
Lead Sponsor | Collaborator |
---|---|
Follicle Pharma Ltd |
Israel,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in hair count | Change in total hair count, vellus and non-vellus hair count per cm^2 as assessed by Phototrichogram | 28 weeks | |
Other | Change in total hair density | Change in total hair density per cm^2 as assessed by Phototrichogram | 28 weeks | |
Other | Change in hair thickness | Change in cumulative diameter and hair thickness per cm^2 as assessed by Phototrichogram | 28 weeks | |
Other | Exploratory Endpoint: Efficacy - self-assess | Subject self-assessment by questionnaire | 28 weeks | |
Primary | Safety of product application | Adverse event reporting (local and general) | 28 weeks | |
Secondary | Tolerability & Usability | Subject self-assessment by questionnaire | 28 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06110377 -
MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine)
|
Phase 4 | |
Completed |
NCT03676400 -
Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia
|
N/A | |
Recruiting |
NCT05938569 -
Computer-Assisted Hair Restoration Study Using ARTAS System
|
N/A | |
Not yet recruiting |
NCT06326359 -
Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
|
N/A | |
Recruiting |
NCT05426629 -
Hydraderm for Androgenic Alopecia
|
Phase 4 | |
Recruiting |
NCT05827991 -
A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia
|
N/A | |
Recruiting |
NCT05369481 -
Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia
|
N/A | |
Not yet recruiting |
NCT06292533 -
Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study
|
N/A | |
Completed |
NCT02824380 -
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia
|
Phase 1 | |
Completed |
NCT06112782 -
Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality
|
N/A | |
Completed |
NCT02594046 -
The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia
|
N/A | |
Recruiting |
NCT05435625 -
Fractional Laser Versus Radiofrequency in Androgenetic Alopecia
|
N/A | |
Completed |
NCT05450861 -
Effect of the Composition From Fish on Promoting Hair Growth
|
N/A | |
Completed |
NCT03506503 -
Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia
|
N/A | |
Completed |
NCT03467412 -
To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin
|
Phase 2 | |
Completed |
NCT01852487 -
Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia
|
N/A | |
Not yet recruiting |
NCT03474718 -
Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia
|
Early Phase 1 | |
Active, not recruiting |
NCT02914587 -
Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study
|
N/A | |
Completed |
NCT04341363 -
Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
|
N/A | |
Completed |
NCT04450602 -
A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss
|
N/A |